Biogen (BIIB) Tops Q3 EPS by 71c, Updates Guidance, Approves $5 Billion Buyback

October 21, 2020 7:05 AM

(Updated - October 21, 2020 7:06 AM EDT)

Biogen (NASDAQ: BIIB) reported Q3 EPS of $8.84, $0.71 better than the analyst estimate of $8.13. Revenue for the quarter came in at $3.38 billion versus the consensus estimate of $3.35 billion.


Biogen sees FY2020 EPS of $32.50-$33.50, versus the consensus of $34.77.

The PDF could not be displayed inside the page, click here to open.

For earnings history and earnings-related data on Biogen (BIIB) click here.


Earnings Guidance Hot Buybacks Hot Earnings Hot Guidance Stock Buybacks